Synthetic lethality as a basis to select drug combinations

Genomic analysis of childhood tumours; biological and therapeutic implications

Patient-specific peptide vaccines

Proteogenomics in cancer research

Novel models to personalise cancer therapeutics

Lenalidomide with CD19 antibodies in L-MIND

Denosumab or zoledronic acid for bone disease in multiple myeloma

Hemcare - multiple myeloma learning programme

Extended followup indicates daratumumab with bortezomib and dexamethasone for relapsed MM

Impact of mutational profile at diagnosis for MDS/CML

Triplet therapy for all comers in the CLL-BAG trial

The role of patient advocates in trial design, participation